Educational profiles only. Typical protocols are how these compounds are commonly logged — not recommended doses. Research-only compounds are labeled as such.
A gastric pentadecapeptide studied for tissue repair. Commonly logged as a daily or twice-daily subcutaneous research compound.
250–500 mcg · daily · Research only — not approved
A thymosin-β4 fragment logged on loading (twice weekly) then maintenance (weekly) schedules. Dose scale is milligrams, not micrograms.
2–5 mg · 2× / week · Research only — not approved
A copper-binding tripeptide used topically and as a reconstituted vial. Mixed solution is characteristically blue.
1–2 mg · daily · Research only — not approved
A common two-component blend (typically BPC-157 + TB-500). One draw decrements both ledgers.
250–500 mcg · daily · Research only — not approved
A selective ghrelin-receptor agonist with a short half-life. Often logged 1–3× daily, frequently at bedtime, fasted.
100–300 mcg · daily · Research only — not approved
A GHRH analog without Drug Affinity Complex. Half-life is measured in minutes — not interchangeable with DAC.
100–200 mcg · daily · Research only — not approved
GHRH analog with Drug Affinity Complex. Logged weekly or twice weekly — not daily.
1000–2000 mcg · weekly · Research only — not approved
A GHRH analog with an FDA indication for HIV-associated lipodystrophy (branded Egrifta). Brand kits do not use generic BAC math.
2 mg · daily · Approved for other indications
A GHRH fragment often logged nightly, fasted, on a 5/2 or 8–12 week cycle.
200–500 mcg · 5 on / 2 off · Compounded / off-label
An oral ghrelin-receptor agonist. Logged as milligrams swallowed, not a reconstitution.
10–25 mg · daily · Research only — not approved
A GLP-1 receptor agonist. Branded pens and compounded vials are different objects — concentration must come from the label.
0.25–2.4 mg · weekly titration · Approved for other indications
A dual GIP/GLP-1 agonist. Weekly titration is the usual protocol shape. Pens are fixed-dose; compounded vials need a locked concentration.
2.5–15 mg · weekly titration · Approved for other indications
An investigational triple agonist. Not FDA-approved. Elevated disclaimer required on first add.
1–4 mg · weekly · Investigational
Daily GLP-1 pen. Logged in milligrams, not reconstitution units.
0.6–3 mg · daily · Approved for other indications
An ACTH analog fragment commonly prepared as an intranasal spray. Log sprays × mcg/spray, not syringe units.
200–600 mcg · daily · Research only — not approved
A tuftsin analog often paired with Semax as an intranasal log.
200–500 mcg · daily · Research only — not approved
A nonapeptide historically studied around sleep architecture. Logged at bedtime by some users.
100–200 mcg · 3× / week · Research only — not approved
A melanocortin agonist. Branded Vyleesi is an autoinjector. Research vials are PRN, not a daily protocol.
0.5–1.75 mg · as needed · Approved for other indications
A melanocortin agonist logged as a short load then infrequent maintenance. Photosensitivity notes matter.
250–500 mcg · daily · Research only — not approved
A modified hGH fragment logged as a fasted morning subcutaneous research compound.
250–500 mcg · 5 on / 2 off · Research only — not approved
A mitochondrial-encoded peptide logged in milligrams, often a few times per week.
5–10 mg · 2× / week · Research only — not approved
A mitochondria-targeted tetrapeptide under clinical investigation.
4–10 mg · 2× / week · Investigational
A KISS1R agonist logged as a pulse, not a daily secretagogue.
100–200 mcg · 2× / week · Research only — not approved
Native GnRH. Diagnostic and pulsatile protocols are different objects. Short reconstituted BUD.
50–200 mcg · 3× / week · Approved for other indications
A redox cofactor logged as subcutaneous, nasal, or clinic IV. Injection volumes can exceed 1 mL.
50–200 mg · 2× / week · Compounded / off-label
An endogenous tripeptide logged as clinic IV or self-administered IM/SubQ.
100–200 mg · 2× / week · Compounded / off-label
A tetrapeptide logged in short cycles rather than indefinitely.
5–10 mg · daily · Research only — not approved
A thymic peptide with approved use in some countries. Logged in milligrams, typically a few times per week.
1.6–3.2 mg · 2× / week · Approved for other indications
A human cathelicidin fragment logged as a research immune peptide.
50–100 mcg · daily · Research only — not approved
An α-MSH tripeptide fragment logged for local or systemic research protocols.
200–500 mcg · daily · Research only — not approved
An oral NNMT inhibitor. Logged as capsules, not a reconstitution.
50–150 mg · daily · Research only — not approved
Recombinant growth hormone. The only catalog item that should use the 3 IU ≈ 1 mg conversion by default.
1–2 IU · daily · FDA-approved (labeled use)
A glycoprotein hormone labeled in IU. Conversion is ~9,000 IU per mg — not the HGH factor.
504–5004 IU · 3× / week · FDA-approved (labeled use)